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Allison Wyman4, Sophie Rushton-Smith4 and Joel M Gore4, for the Euro-STAT Investigators
Abstract
Introduction: Although effective strategies are available for the management of chronic hypertension, less is
known about treating patients with acute, severe elevations in blood pressure. Using data from the European
registry for Studying the Treatment of Acute hyperTension (Euro-STAT), we sought to evaluate ‘real-life’
management practices and outcomes in patients who received intravenous antihypertensive therapy to treat an
episode of acute hypertension.
Methods: Euro-STAT is a European, hospital-based, observational study of consecutive adult patients treated with
intravenous antihypertensive therapy while in the emergency department, perioperative unit or ICU. Enrolment
took place between 1 July and 15 October 2009 in 11 hospitals in 7 European countries (Austria, Belgium,
Germany, Italy, Spain, Sweden and the United Kingdom).
Results: The study population was composed of 791 consecutive patients (median age 69 years, 37% women).
Median arterial blood pressure before treatment was 166 mmHg systolic blood pressure (IQR 141 to 190 mmHg)
and 80 mmHg diastolic blood pressure (IQR 68 to 95). Nitroglycerine was the most commonly used
antihypertensive treatment overall (40% of patients), followed by urapidil (21%), clonidine (16%) and furosemide
(8%). Treatment was associated with hypotension in almost 10% of patients. Overall 30-day mortality was 4%, and
new or worsening end-organ damage occurred in 19% of patients.
Conclusions: High blood pressure requiring intravenous therapy is currently managed with a variety of agents in
Europe, with those most commonly used being nitroglycerine, urapidil and clonidine. Patients with acute
hypertension have substantial concomitant morbidity and mortality, and intravenous antihypertensive treatment is
associated with hypotension in almost 10% of cases.
Introduction
Over 1 billion people worldwide are estimated to have
hypertension [1,2], which increases their risk of cardio-
vascular morbidity and mortality [3,4] and organ injury
[5,6]. One percent of all hypertensive patients experi-
ence at least one episode of acute, severe hypertension,
necessitating intravenous (IV) antihypertensive therapy
and placing these patients at risk of overt, acute end-
organ damage over their lifetime. The actual prevalence
may in fact be much higher [7,8]. One-fourth of patients
who present to busy emergency departments (EDs) have
acute, severe hypertension [7,8]. In the present study,
we defined this population by using a pragmatic
approach according to whether the treating physicians
decided to use IV antihypertensive therapy.
Multiple effective strategies are used for the manage-
ment of chronic hypertension [1], but less is known
about treating patients who present with acute, severe
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elevations in arterial blood pressure (BP). The optimal
target for BP lowering has yet to be defined; the defini-
tions of hypertensive urgencies, emergencies and out-
come measures lack uniformity; evidence supporting the
use of one drug over another is lacking; and whether
certain treatments are better than others is unknown
[7]. As a consequence, treatment practices vary [9]. The
European registry for Studying the Treatment of Acute
hyperTension (Euro-STAT) was conducted to evaluate
‘real-life’ management practices and outcomes in
patients treated with IV antihypertensive therapy for an
episode of acute hypertension.
Methods
Study design
Euro-STAT is a European, hospital-based, observational
study of consecutive patients treated with IV antihyper-
tensive therapy while in the critical care setting. Enrol-
ment took place between 1 July and 15 October 2009 in
11 hospitals in 7 European countries (Austria, Belgium,
Germany, Italy, Spain, Sweden and the United
Kingdom).
The study sites were selected to include a mix of pub-
lic and private hospitals across a broad geographic area
to ensure a rich and diverse population of patients
(Table 1). Participating sites had institutional research
board approval for the study and adhered to local regu-
latory and ethical rules. Patient consent was waived in
Austria, Belgium, Germany, Italy, Sweden and the Uni-
ted Kingdom, and oral patient consent was required in
Spain. The registry was conducted in accordance with
European Union directives on the protection of human
subjects in research, local ethical guidelines and the
Guidelines for Good Epidemiological Practice http://
www.ieaweb.org/index.php?view=article&catid=20:good-
epidemiological-practice-gep&id=15:good-epidemiologi-
cal-practice-gep&format=pdf&option=com_content&Ite-
mid=43. The patients provided their written informed
consent to participate if required to do so by local ethi-
cal committees. As Euro-STAT is an observational regis-
try, no specific treatments, tests or procedures were
mandated or withheld from the patients.
Study objectives
The objectives of the registry were (1) to improve the
understanding of the characteristics of patients with
acute BP elevation cared for in EDs, perioperative units
and ICUs; (2) to describe contemporary IV management
practices, including the timing of treatment initiation,
medications used to control BP within selected ranges
and the time required to achieve BP control; and (3) to
determine in-hospital and postdischarge outcomes as
they relate to the management of an episode of acute
hypertension. A preliminary goal was to establish the
rates of key variables, which could then be used to
develop formal sample size estimates for a planned lar-
ger study in the same setting.
Patient selection and enrolment criteria
Consecutive adult male and female patients at least 18
years of age with a qualifying episode of acute hyperten-
sion on or after 1 July 2009 were identified by trained
data abstractors through prospective identification of
patients admitted to EDs, perioperative units and ICUs.
To qualify for enrolment, a patient had to meet the fol-
lowing two criteria: (1) The clinician had to have
attempted BP control with either an IV infusion or at
least two IV boluses of an antihypertensive drug, and (2)
the initial treatment had to have been started within 24
hours of the patient’s arrival in the ED, at any time dur-
ing the perioperative period (defined as the time from
the initiation of anaesthesia to discharge from the posta-
naesthesia recovery area) or within 14 days of ICU
admission.
Patients were excluded from participating in the study
if they had received IV antihypertensive treatment
Table 1 Sites and investigators participating in Euro-STAT
Country Site National coordinator/investigator
Austria AKH General Hospital Michael J Hiesmayr
Belgium Erasme University Hospital Jean-Louis Vincent
Germany Universitätsklinik Bonn Andreas Hoeft
Germany Charité-Universitätsmedizin Claudia Spies
Italy Università degli Studi di Firenze A Raffaele De Gaudio
Italy Sant’Andrea Hospital Salvatore Di Somma
Spain Hospital de Sabadell Antonio Artigas
Sweden Karolinska Universitetssjukhuset, Solna Jan Ostergren
United Kingdom New Cross Hospital Wolverhampton Giampaolo Martinelli
United Kingdom Papworth Hospital NHS Trust Alain Vuylsteke
United Kingdom Southampton General Hospital David Smith
Euro-STAT, European registry for Studying the Treatment of Acute hyperTension; NHS, National Health Service.
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initiated in a transferring hospital, if they were admitted
for burn treatment, if they had drug-induced (iatrogenic)
hypertension, if the qualifying event had occurred while
being treated with comfort measures only, and if medi-
cal records were not available. ED patients were
excluded if they were transferred directly from the ED
to another healthcare facility after initiation of IV anti-
hypertensive treatment. Perioperative patients were
excluded if they had planned perioperative controlled
hypotension and if the qualifying event occurred before
the induction of anaesthesia.
Data acquisition
All eligible patients were assigned a unique study identi-
fication number, and abstractors completed a standar-
dised case report form that had been piloted and
subsequently validated. Data were abstracted from hos-
pital medical records.
Outcome measures
The main clinical outcome measures were all-cause in-
hospital mortality, end-organ injury (including ischaemic
stroke, encephalopathy (defined as acute mental status
changes without other identifiable causes), acute coron-
ary syndrome, congestive heart failure, renal insuffi-
ciency (’chronic kidney failure’ was defined as previously
diagnosed renal insufficiency or documentation of crea-
tinine clearance less than 60 ml/minute before admis-
sion) and aortic dissection), and survival at 30 days
following hospital discharge.
Data quality and management
Training material and guidelines for data abstractors
were developed by the data-coordinating centre at the
Center for Outcomes Research (COR) at the University
of Massachusetts Medical School (Worcester, MA,
USA). A one-day course was held at each enrolling hos-
pital to maintain common definitions, improve data
abstraction and address training needs.
Data were collected, handled and analysed indepen-
dently of the sponsor by the data-coordinating centre.
Study coordinators at COR reviewed the data collection
forms to identify variances from norms and missing
data and followed up with the principal investigators by
mail or by telephone to resolve any queries.
Statistical analyses
Descriptive statistics were calculated for all patients.
Data are summarised as means (± SD) or as medians
(25% and 75% percentiles) for continuous data and as
counts and percentages for categorical data. All results
shown are univariate and unadjusted. No variable had a
level of missing data greater than 10%. Any missing data
were simply excluded from the analyses. All eligible
patients underwent chart review, and there was no loss
to follow-up. Patients’ charts were reviewed until the
patient’s death or discharge from the hospital up to 30
days after initiation of IV antihypertensive therapy
(whichever came first). Statistical analyses were per-
formed using the SAS version 9.2 software package
(SAS Institute, Cary, NC, USA).
Results
Overview of study population
The study population comprised 791 consecutive
patients with a median age of 69 years, and 37% were
women (Table 2). In the overall cohort, 62% had a his-
tory of hypertension, 24% had diabetes mellitus, 14%
had undergone previous cardiac surgery (including cor-
onary artery bypass graft or valve surgery) and 12% had
had a prior myocardial infarction. Patients who were
treated during the perioperative period were the young-
est and had the highest numerical rates of peripheral
vascular disease, tobacco smoking and alcohol misuse
compared with the other patients. Patients admitted to
the ED were older than the postoperative and ICU
populations. The prevalence of history of hypertension
(including prior hospitalisation for hypertension), dia-
betes, neurological disease or dysfunction, chronic kid-
ney disease and end-stage kidney disease was
numerically highest among the ED population. The ICU
population had the highest prevalence of cardiac surgery
and previous myocardial infarction.
The overall median (IQR) initial and peak creatinine
values were 89 μmol/L (72 to 113 μmol/L) and 103
μmol/L (82 to 146 μmol/L), and these values were high-
est among patients admitted to the ED and lowest
among perioperative patients. The median (IQR) arterial
pressure at the initiation of treatment was 166 mmHg
for systolic blood pressure (SBP) (141 to 190 mmHg)
and 80 mmHg for diastolic blood pressure (DBP) (68 to
95 mmHg) (Table 3). The initial BP values were highest
among the ED patients.
Intravenous antihypertensive drugs
The median number (IQR) of IV antihypertensive drugs
used during the first three hours was 1 (1 to 2) overall
and was similar across the clinical settings: 1 (1 to 2) in
ED and perioperative patients and 1 (1 and 1) in ICU
patients. The four most frequently used IV antihyper-
tensive drugs in each clinical setting are shown in Figure
1. Nitroglycerine was the most commonly used drug
overall (40% of patients), driven largely by its high rate
of use among ICU patients (60%). Urapidil and clonidine
were the next most frequently used drugs overall, which
was due to the high rates of use among perioperative
patients. Furosemide was the fourth most often used
drug and the most commonly used treatment in the ED
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population. Among the ED patients whose first IV treat-
ment was nitroglycerine, hypertension was the most
common admitting diagnosis (n = 16, 33%), followed by
acute coronary syndrome (n = 8, 16%), chest pain, and
heart failure or pulmonary oedema (both n = 6, 12%).
In each group, more than 90% of patients achieved a
10% decrease in SBP within the first 72 hours following
initiation of IV antihypertensive therapy. The median
time to 10% decrease was 28 minutes after starting the
antihypertensive drug. The following is the breakdown
of patients who did not achieve a 10% decrease within
72 hours: 6 of 180 ED patients (3.3%), 22 of 382 ICU
patients (5.8%) and 8 of 229 perioperative patients
(3.5%).
Emergency department patients
Among the 180 patients who presented to the ED, the
most common symptoms were shortness of breath (n =
60, 33%) and chest pain (n = 50, 28%) and, less fre-
quently, headache (n = 20, 11%), focal neurological defi-
cit (n = 18, 10%) and altered mental status (n = 13,
7.2%). The most common presumptive primary diag-
noses were hypertension, heart failure or pulmonary
oedema, stroke, acute coronary syndrome or myocardial
infarction, and chest pain (Figure 2A).
The median (IQR) number of hours in the ED was 8.0
(4.0 to 20), the minimum ED stay was one-half hour
and the maximum stay was 144 hours. Most ED patients
(n = 155, 95%) had their IV antihypertensive treatment
started in the ED; 9 patients (5.5%) had it started in the
ambulance; 4.4% experienced an episode of hypotension
requiring discontinuation of the antihypertensive drug,
and/or the administration of vasopressors or fluids, or
reverse Trendelenburg positioning within 72 hours of
starting treatment; and 3.3% relapsed (requiring resump-
tion of IV antihypertensive treatment) within 72 hours
of discontinuation of the initial IV treatment.
The majority of the ED patients were admitted to a
non-ICU inpatient unit (n = 104, 58%). Fifty-three
patients (29%) were discharged to home, 16 (8.9%) were
admitted to the ICU, 5 (2.8%) left against medical advice
and 2 (1.1%) died in the ED.
Perioperative patients
The preoperative diagnoses of the 229 perioperative
patients are shown in Figure 2B. Most operating or
recovery room patients had undergone cardiac (40%),
gastrointestinal (17%), orthopaedic (11%) or vascular
(9.2%) surgery. The median duration of surgery was 190
minutes. Nearly one-half of the patients (n = 112, 49%)
had undergone cardiac surgery and were evaluated on
the basis of their EuroSCORE (European System for
Cardiac Operative Risk Evaluation; available at http://
www.euroscore.org/). The median score (IQR) was 2.5
(1.2 to 6.4; minimum 0, maximum 68.6), which is
equivalent to a median predicted mortality rate of 2.5%
(1.2% to 6.4%). For most patients (n = 143, 67%) IV
antihypertensive treatment started in the operating
Table 2 Baseline characteristics of the study population
Variables All patients
(N = 791)
Enrolment setting
ED
(n = 180)
ICU
(n = 382)
Perioperative
(n = 229)
Median age, years (IQR) 69 (58 to 77) 70 (60 to 79) 69 (59 to 76) 66 (53 to 76)
Females, n (%) 295 (37) 94 (52) 107 (28) 94 (41)
Medical history, n (%)
Hypertension 491 (62) 126 (70) 230 (60) 135 (59)
Hospitalisation for hypertension 7 (0.9) 6 (3.3) 0 (0.0) 1 (0.4)
Cardiac surgery 108 (14) 6 (3.3) 71 (19) 31 (14)
Myocardial infarction 96 (12) 19 (11) 56 (15) 21 (9.2)
Diabetes mellitus 189 (24) 49 (27) 88 (23) 52 (23)
Chronic kidney disease 80 (10) 25 (14) 43 (11) 12 (5.2)
End-stage renal disease 18 (2.3) 5 (2.8) 10 (2.6) 3 (1.3)
Neurological dysfunction or disease 91 (12) 29 (16) 45 (12) 17 (7.4)
Peripheral vascular disease 91 (12) 13 (7.2) 47 (12) 31 (14)
Tobacco smoker 176 (22) 30 (17) 83 (22) 63 (28)
Alcohol misuse (≥2 drinks/day) 45 (5.7) 2 (1.1) 23 (6.0) 20 (8.7)
Drug abuse (amphetamines, cocaine, other) 2 (0.3) 1 (0.6) 1 (0.3) 0 (0.0)
Predisposing factors, n (%)
Medication nonadherence (ED) - 11 (6.1) - -
Medications withheld > 12 hours (ICU and perioperative) - - 39 (10) 21 (9.2)
ED, emergency department; -, no data.
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room or theatre, and in 33% (n = 71) it was begun after
surgery. Postoperatively, 57% (n = 130) of the patients
were transferred to a postanaesthesia recovery area, 31%
(n = 72) were transferred directly to the ICU and 12%
(n = 27) were transferred directly to an inpatient ward
or unit. Ten percent of patients experienced an episode
of hypotension within 72 hours of starting treatment,
and 4.8% of patients relapsed within 72 hours of the dis-
continuation of the initial IV treatment. Thirty-nine per-
cent (n = 89) of patients received two or more different
IV antihypertensive drugs.
ICU patients
Most ICU patients (304 of 382, 80%) were direct post-
operative admissions (that is, patients whose initial
acute, severe hypertension developed after ICU admis-
sion). Their primary diagnoses are shown in Figure 2C.
The majority of patients in the ICU population were
cardiac or cardiac surgery patients (62%), 25% were
mixed surgical and medical patients, 7% were surgical
patients, 4% were medical patients and 3% were classi-
fied as ‘other’. Patients spent a median (IQR) of 3 days
(2 to 6) in the ICU. Among ICU patients, the minimum
stay was 1 day and the maximum stay was 54 days.
Thirteen patients (3.4%) died in the ICU. The median
time (IQR) in the ICU before IV treatment began was
3.4 hours (0.6 to 18). Overall, 8.4% of ICU patients
experienced an episode of hypotension within 72 hours
of the start of IV antihypertensive treatment, 6.0%
relapsed within 72 hours of discontinuation of the initial
Table 3 Blood pressure, laboratory values, end-organ damage and outcomes (in-hospital)
Variables All patients
(n = 791)
Enrolment setting
ED (n = 180) ICU (n = 382) Perioperative
(n = 229)
Median blood pressure, mmHg (IQR)
Qualifying SBP 166 (141 to
190)
200 (174 to 220) 160 (138 to 180) 160 (140 to
180)
Qualifying DBP 80 (68 to 95) 100 (90 to 110) 73 (64 to 85) 80 (68 to 90)
Median time from qualifying BP to initiation of IV antihypertensive therapy,
minutes (IQR)
5.0 (2.0 to 17) 20 (5.0 to 30) 5.0 (1.0 to 15) 5.0 (1.0 to 5.0)
Median time from IV initiation to 10% decrease in SBP, minutes (IQR) 28 (11 to 60) 31 (18 to 87) 30 (12 to 70) 18 (8.0 to 43)
Median laboratory values (IQR)
Peak troponin 0.03 (0.01 to
0.23)
0.03 (0.01 to 0.12) 0.04 (0.01 to 0.33) 0.03 (0.01 to
0.23)
Peak creatine kinase-MB 33 (9.4 to 88) 5.1 (3.8 to 78) 50 (31 to 152) 38 (24 to 79)
Peak NT-proBNP 910 (295 to 2,
240)
1, 672 (429 to 2,
637)
1, 451 (428 to 2,
709)
359 (242 to
970)
Peak BNP 99 (82 to 132) 116 (91 to 146) 20 (20 to 20) n/a
Initial creatinine, μmol/L 89 (72 to 113) 94 (78 to 125) 91 (74 to 116) 83 (69 to 102)
Peak creatinine, μmol/L 103 (82 to 146) 119 (99 to 222) 107 (84 to 151) 92 (73 to 122)
End-organ injurya, n (%)
Acute coronary syndrome (new) 25 (3.2) 22 (12) 2 (0.5) 1 (0.4)
Previous worsened 10 (1.3) 8 (4.4) 2 (0.5) 0 (0.0)
Acute LV dysfunction/pulmonary oedema (new) 28 (3.5) 19 (11) 7 (1.8) 2 (0.9)
Previous worsened 20 (2.5) 16 (8.9) 4 (1.1) 0 (0.0)
Aortic dissection (new) 5 (0.6) 2 (1.1) 3 (0.8) 0 (0.0)
Previous worsened 2 (0.3) 1 (0.6) 1 (0.3) 0 (0.0)
Encephalopathy (new) 22 (2.8) 8 (4.4) 11 (2.9) 3 (1.3)
Previous worsened 2 (0.3) 1 (0.6) 0 (0.0) 1 (0.4)
Acute kidney failure (new) 36 (4.6) 8 (4.4) 23 (6.0) 5 (2.2)
Previous worsened 19 (2.4) 5 (2.8) 12 (3.1) 2 (0.9)
Stroke (new) 13 (1.6) 8 (4.4) 5 (1.3) 0 (0.0)
Previous worsened 7 (0.9) 3 (1.7) 2 (0.6) 2 (0.9)
Outcomes n (%)
ICU admission 114 (14) 17 (9.4) 19 (5.0)b 78 (34)
Hypertension relapse 104 (13) 14 (7.8) 55 (14) 35 (15)
BP = blood pressure; DBP = diastolic blood pressure; ED = emergency department; IV = intravenous; LV = left ventricular; n/a = not applicable; NT-proBNP = N-
terminal prohormone of brain natriuretic peptide; SBP = systolic blood pressure. aCategories are not mutually exclusive. bReadmission to ICU.
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IV treatment, and 17% required treatment with more
than one agent. Upon discharge, 90% (n = 343) of the
patients were transferred to an inpatient unit, 3.7% (n =
14) were transferred to another healthcare facility, 2.9%
(n = 11) were discharged to home and 0.3% (n = 1) left
against medical advice.
Thirty-day outcomes
The overall rate of 30-day death rate was 4%, and the
overall rate of new or worsening end-organ damage was
19%. The rates of both outcomes were highest among
patients in the ED (6% and 43%, respectively), inter-
mediate in the ICU patients (5% and 15%, respectively)
and lowest among patients in the perioperative setting
(2% and 7%, respectively).
Discussion
These contemporary data derived from the Euro-STAT
study demonstrate heterogeneous patterns of care for
patients presenting with acute elevation of BP across a
range of acute care settings, with high rates of morbidity
and mortality. Of the 791 patients included in Euro-
STAT, 48% were treated for acute hypertension in the
ICU. Many of them had undergone surgery and devel-
oped severe hypertension postoperatively, 29% devel-
oped it perioperatively and 23% developed it in the ED.
Median BP was higher among patients treated in the ED
(200/100 mmHg) than in those treated in the ICU (160/
73 mmHg) or perioperatively (160/80 mmHg).
The Studying the Treatment of Acute Hypertension
(STAT) registry in the United States [9,10] involved
patients with a qualifying episode of acute, severe hyper-
tension (that is, (1) SBP greater than 180 and/or DBP
greater than 110 mmHg or (2) SBP above 140 mmHg
and/or DBP greater than 90 mmHg when presenting
with subarachnoid haemorrhage) who received IV anti-
hypertensive therapy in a critical care setting. Compared
with the STAT study, the patients’ median age in the
Euro-STAT study was higher (69 vs 58 years) and fewer
patients had a history of hypertension (62% vs 89%).
Overall, the median BP was lower in the Euro-STAT
study than in the STAT study (166/80 vs 200/110
mmHg). This finding could indicate that patients in the
Euro-STAT study had less severe hypertension, or it
could be related to the different qualifying criteria and
hence the distribution of patients in the STAT studies.
Figure 1 Most frequent first intravenous antihypertensive drugs used across patient groups.
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In Euro-STAT, perioperative patients were also
included, and there were many more ICU patients
(mainly in a postoperative context) than there were in
the STAT study.
The decision to amalgamate ED, perioperative and
ICU patients was made because the purpose of this
descriptive study was to evaluate the efficacy of IV ther-
apy for the control of elevated BP level in different loca-
tions within a hospital, thereby assessing similarities and
differences in treatments and outcomes in different
contexts.
The first antihypertensive drug used varied by treat-
ment location. In the ICU, nitroglycerine was by far the
most widely used (60%); in the ED, furosemide was used
in 34% of patients and nitroglycerine was used in 27%;
and perioperatively, urapidil was used in 34% of patients
and clonidine was used in 28%. The high use of furose-
mide in the ED (34%) indicates that pulmonary oedema
associated with high BP was the likely primary diagnosis,
which is backed up by the higher rates of new or wor-
sened acute coronary syndrome (17% vs 1.1% and 0.5%)
and acute left ventricular dysfunction (19.4% vs 2.9%
Figure 2 Presumptive primary admitting diagnoses. (A) Emergency department patients. (B) Perioperative patients. (C) ICU patients. ACS =
acute coronary syndrome; HF = heart failure; MI = myocardial infarction.
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and 0.9%) in ED vs ICU and perioperative patients,
respectively. In Euro-STAT overall, the most frequently
used antihypertensive drugs were nitroglycerine (40%),
urapidil (21%), clonidine (16%) and furosemide (8.3%).
This pattern is very different from the results of the
STAT study, where the most common initial antihyper-
tensive drugs were labetalol (32%), metoprolol (17%),
nitroglycerine (15%) and hydralazine (15%) [9]. The var-
iations in drug use between the Euro-STAT and STAT
studies may reflect differences in the drugs available in
these regions. The percentage of patients who required
a second IV antihypertensive was 34% in both the Euro-
STAT and STAT studies.
This variability in treatment between continents, stu-
dies and hospital departments is not surprising, given
the paucity of evidence regarding the superiority of one
drug over another and the absence of guidelines for the
treatment of acute hypertension. There are, however,
various papers that have provided recommendations
that are not evidence-based. Acute hypertension can be
split into hypertensive emergencies (severe BP elevation
with evidence of impending or progressive end-organ
damage) and hypertensive urgencies (severe BP elevation
without progressive target organ dysfunction) [1]. In
general, hypertensive urgencies can be treated with oral
antihypertensive drugs [11], and researchers who pub-
lished a recent meta-analysis found angiotensin-convert-
ing enzyme inhibitors to be superior to calcium channel
blockers [12]. Hypertensive emergencies generally
require IV treatment to achieve a rapid decrease in BP,
and patients admitted to these care settings may be
sicker than patients treated with oral agents. Recom-
mendations (based on expert consensus due to a lack of
clinical trials) for which antihypertensive to use based
on different disease states are shown in Table 4[13].
While nitroglycerine should be used as an adjunctive
therapy, the high rates of use in the Euro-STAT popula-
tion likely reflect familiarity with its use, together with
its ease of administration, titration and rapid reversibil-
ity. In the ED, the ICU and perioperatively, 4.4%, 8.4%
and 10% of patients, respectively, had hypotension
within 72 hours of the start of treatment, resulting in
(1) discontinuation of the antihypertensive drug or (2)
treatment with vasopressors, fluids or reverse Trende-
lenburg positioning. The overall incidence of hypoten-
sion in the Euro-STAT study was higher than that in
the STAT study (8.1% vs 4.0%) [9].
As expected, mortality rates at discharge from the
ICU, ED or surgical department in the Euro-STAT
study were highest among ICU patients (3.4% vs 1.1% of
ED patients and 0% of perioperative patients). Total in-
hospital mortality in the Euro-STAT study was highest
among ED patients (5.7% vs 5.1% of ICU patients and
2.3% of perioperative patients), which is lower than the
comparable rate in the STAT study (6.9%) [9]. New or
worsened end-organ damage was observed in 43% of ED
patients, 15% of ICU patients and 6.6% of perioperative
patients.
Limitations
The observational Euro-STAT registry is a relatively
small data set, and the sites may not be representative
of all hospitals in Europe. Treatment choices may there-
fore be biased by institution choices. Also, populations
of acute hypertension are heterogeneous and are likely
to differ by country. Amalgamation of all countries into
one data set therefore gives an overview, but no coun-
try-specific data. As our entry criteria required the phy-
sician to initiate IV antihypertensive therapy, there was
no comparison with other patients in relation to mor-
bidity. Also, we do not have complete information on
post-hospital discharge follow-up. Furthermore, we do
not know what happened to patients for whom a reduc-
tion in BP was not achieved despite treatment.
Conclusions
Acute hypertension is currently managed with a wide
range of IV agents in the various clinical settings in
which it arises. These patients have substantial concomi-
tant morbidity and mortality, and IV antihypertensive
treatment is associated with hypotension in almost 10%
of patients. Further data are required to identify optimal
Table 4 Recommended treatments for hypertensive emergenciesa
Emergency type Esmolol Fenoldopam Labetalol Nicardipine Nitroglycerine Sodium nitroprusside
Pulmonary oedema + systolic dysfunction Yes Yes Yesb Yes
Pulmonary oedema + diastolic dysfunction Yes Yes Yesb Yes
Myocardial infarction Yesc Yesc Yesb
Aortic dissection Yes Yes Yes
Postoperative hypertension Yes Yes Yes
Hypertensive encephalopathy Yes Yes Yes
Kidney failure Yes Yes
Stroke Yes Yes Yes
aAdapted from Smithburger et al. [13]. bAs adjunctive therapy. cIn combination with intravenous nitroglycerine.
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management strategies for these patients, thereby ensur-
ing the best possible outcomes.
Key messages
• High blood pressure requiring intravenously admi-
nistered drug therapy is currently managed with a
variety of agents in Europe, with the most commonly
used being nitroglycerine, urapidil and clonidine.
• Intravenous antihypertensive treatment is asso-
ciated with hypotension in almost 10% of patients.
• Patients with acute, severe hypertension have sub-
stantial concomitant morbidity and mortality.
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